CHGCY (Chugai Pharmaceutical Co) EPS (Basic): $0.90 (TTM As of Mar. 2026)


CHGCY Chugai Pharmaceutical Co Ltd CHGCY
92 GF Score
Price $22.99
GF Value $24.28
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co EPS (Basic)?

Chugai Pharmaceutical Co CHGCY +0.13% 92 EPS (Basic) is $0.90 as of Mar. 2026. GuruFocus rates CHGCY with a GF Score™ of 92/100 and a GF Value™ of $24.28 (Fairly Valued). The stock has 1 warning sign investors should review.

Chugai Pharmaceutical Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.90.

Chugai Pharmaceutical Co's EPS (Diluted) for the three months ended in Mar. 2026 was $0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.90.

Chugai Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2026 was $0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.91.

During the past 12 months, Chugai Pharmaceutical Co's average EPS without NRIGrowth Rate was 10.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 12.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Chugai Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 47.70% per year. The lowest was -17.40% per year. And the median was 11.55% per year.

Chugai Pharmaceutical Co  (OTCPK:CHGCY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Chugai Pharmaceutical Co EPS (Basic) Related Terms

Chugai Pharmaceutical Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co EPS (Basic) Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.84 0.69 0.77 0.85

Chugai Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.20 0.23 0.25 0.22
CHGCY
92GF Score
Chugai Pharmaceutical Co Ltd CHGCY
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Chugai Pharmaceutical Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(2783.645-0)/3291.323
=0.85

Chugai Pharmaceutical Co's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(727.351-0)/3291.544
=0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.90 mean?
Chugai Pharmaceutical Co (CHGCY) has a EPS (Basic) of $0.90 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's EPS (Basic) too high?
Chugai Pharmaceutical Co's current EPS (Basic) is $0.90. Overall, Chugai Pharmaceutical Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's EPS (Basic) compare to LLY and JNJ?
Chugai Pharmaceutical Co's EPS (Basic) of $0.90 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current EPS (Basic) is $0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCY) is currently considered Fairly Valued. The stock's GF Value™ is $24.28, compared to a current price of $22.99 — trading 5.3% below its estimated fair value. The current EPS (Basic) is $0.90. Chugai Pharmaceutical Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCY), the current EPS (Basic) is $0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (CHGCY) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of $22.99 is trading 5.3% below its estimated GF Value™ of $24.28. GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for CHGCY:

  • EPS (Basic): $0.90
  • GF Value™: $24.28 vs. price of $22.99 (5.3% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the CHGCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
92GF Score

Get the complete analysis for CHGCY

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.99
Price
$24.28
GF Value